OverviewSuggest Edit

TherapeuticsMD operates as a women's health care product company. The Company manufactures and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, and natural menopause relief products under the vitaMedMD brand, as well as generic formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. TherapeuticsMD creates products to address the unique changes and challenges women experience through every stage of their lives.
TypePublic
Founded2008
HQBoca Raton, US
Websitetherapeuticsmd.com
Employee Ratings3.6

Latest Updates

Employees (est.) (Dec 2018)241(+40%)
Job Openings1
Revenue (FY, 2018)$16.1 M(-4%)
Share Price (Mar 2019)$5.2 (-4%)

Key People/Management at TherapeuticsMD

Robert Finizio

Robert Finizio

CEO
Dan Cartwright

Dan Cartwright

CFO
John F. Milligan

John F. Milligan

President
Julia Amadio

Julia Amadio

Chief Product Officer
Brian Bernick

Brian Bernick

Co-Founder & Chief Clinical Officer
Mitchell Krassan

Mitchell Krassan

Chief Strategy Performance Officer
Show more

TherapeuticsMD Office Locations

TherapeuticsMD has an office in Boca Raton
Boca Raton, US (HQ)
6800 Broken Sound Pkwy NW
Show all (1)
Report incorrect company information

TherapeuticsMD Financials and Metrics

TherapeuticsMD Revenue

Embed Graph
View revenue for all periods
TherapeuticsMD's revenue was reported to be $16.10 m in FY, 2018
USD

Revenue (FY, 2018)

16.1m

Gross profit (FY, 2018)

13.4m

Gross profit margin (FY, 2018), %

83%

Net income (FY, 2018)

(132.6m)

EBIT (FY, 2018)

(130.2m)

Market capitalization (22-Mar-2019)

1.3b

Closing stock price (22-Mar-2019)

5.2

Cash (31-Dec-2018)

161.6m

EV

1.2b
TherapeuticsMD's current market capitalization is $1.3 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

8.8m15.0m20.1m19.4m16.8m16.1m

Revenue growth, %

71%34%(4%)

Cost of goods sold

2.0m3.7m4.5m4.2m2.6m2.7m

Gross profit

6.8m11.4m15.6m15.2m14.1m13.4m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

2.3m2.8m3.8m4.2m4.5m4.8m5.2m4.9m4.4m5.5m4.0m4.3m4.4m3.8m3.8m3.5m

Cost of goods sold

648.4k830.7k893.0k1.1m1.0m1.0m1.2m1.1m1.1m1.2m659.6k681.7k700.8k633.6k454.2k699.1k

Gross profit

1.6m2.0m2.9m3.1m3.4m3.8m4.0m3.8m3.3m4.3m3.3m3.6m3.7m3.1m3.3m2.8m

Gross profit Margin, %

72%71%76%74%77%79%77%78%74%78%83%84%84%83%88%80%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

54.2m51.4m64.7m131.5m127.1m161.6m

Accounts Receivable

Inventories

1.0m1.2m690.2k1.1m1.5m3.3m

Current Assets

59.4m56.2m70.7m139.4m139.6m186.8m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(28.4m)(54.2m)(85.1m)(89.9m)(76.9m)(132.6m)

Depreciation and Amortization

58.1k52.5k62.4k132.5k213.1k

Inventories

571.6k(138.5k)492.0k(386.2k)(409.0k)(1.8m)

Accounts Payable

472.9k4.2m(3.2m)4.2m(3.3m)18.6m
USDY, 2018

EV/EBIT

-8.9 x

EV/CFO

-10.9 x

Revenue/Employee

66.8k

Financial Leverage

2.2 x
Show all financial metrics
Report incorrect company information

TherapeuticsMD Online and Social Media Presence

Embed Graph
Report incorrect company information

TherapeuticsMD News and Updates

Thinking about buying stock in Apple, International Business Machines, Square Incorporated, TherapeuticsMD Inc or Yulong Eco-Materials?

NEW YORK, Oct. 29, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, IBM, SQ, TXMD, and YECO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

FDA Approves the First One-Year Contraceptive Fully under a Woman's Control

NEW YORK, Aug. 10, 2018 /PRNewswire/ -- The Population Council, a global nonprofit research organization, announced it has received U.S. Food and Drug Administration (FDA) approval for Annovera™ (segesterone acetate and ethinyl estradiol vaginal system), the first and only contraceptive...

Knight Therapeutics Reports Second Quarter 2018 Results

MONTREAL, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2018.

Thérapeutique Knight publie ses résultats du deuxième trimestre 2018

MONTRÉAL, 09 août 2018 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX:GUD) (« Knight »), société pharmaceutique spécialisée et chef de file au Canada, a publié aujourd’hui ses résultats financiers du deuxième trimestre terminé le 30 juin 2018.

UPDATE 1-FDA approves TherapeuticsMD's hormone therapy

May 30 (Reuters) - The U.S. Food and Drug Administration (FDA) approved TherapeuticsMD Inc's hormone therapy for a painful condition triggered by menopause, giving the women's health company its first approved drug.
Show more
Report incorrect company information

TherapeuticsMD Blogs

TherapeuticsMD Announces Oral Presentations on BIJUVA and ANNOVERA, and Poster Presentations Related to Menopause Symptoms and Treatments at 2019 ISSWSH/ISSM Joint Meeting

BOCA RATON, Fla. --(BUSINESS WIRE)--Mar. 8, 2019-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the schedule of oral presentations on clinical data for BIJUVA TM (estradiol and progesterone capsules, 1 mg/100 mg) and ANNOVERA TM

TherapeuticsMD Announces Participation in Two Upcoming Investor Conferences

TherapeuticsMD Announces Participation in Two Upcoming Investor Conferences Content Import Thu, 02/28/2019 - 07:03 TherapeuticsMD Announces Participation in Two Upcoming Investor Conferences 02/28/19 This release is a backfill from a News Wire G…

TherapeuticsMD Announces Fourth Quarter and Full-Year 2018 Financial Results

TherapeuticsMD Announces Fourth Quarter and Full-Year 2018 Financial Results Content Import Thu, 02/21/2019 - 16:11 TherapeuticsMD Announces Fourth Quarter and Full-Year 2018 Financial Results 02/21/19 This release is a backfill from a News Wire …

TherapeuticsMD to Report Fourth Quarter and Full Year 2018 Results on February 21, 2019

-Executive Management to Host Conference Call on February 21, 2019 at 4:30 p.m. ET - BOCA RATON, Fla. --(BUSINESS WIRE)--Feb. 8, 2019-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its fourth quarter and full year 2018 financial

TherapeuticsMD Announces Participation at 37th Annual J.P. Morgan Healthcare Conference

BOCA RATON, Fla. --(BUSINESS WIRE)--Jan. 3, 2019-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in the 37 th Annual J.P. Morgan Healthcare Conference . Chief Executive Officer Robert G.

TherapeuticsMD Announces Participation in Three Upcoming Investor Conferences

TherapeuticsMD Announces Participation in Three Upcoming Investor Conferences Content Import Mon, 11/12/2018 - 16:33 TherapeuticsMD Announces Participation in Three Upcoming Investor Conferences 11/12/18 This release is a backfill from a News Wire …
Show more

TherapeuticsMD Frequently Asked Questions

  • When was TherapeuticsMD founded?

    TherapeuticsMD was founded in 2008.

  • Who are TherapeuticsMD key executives?

    TherapeuticsMD's key executives are Robert Finizio, Dan Cartwright and John F. Milligan.

  • How many employees does TherapeuticsMD have?

    TherapeuticsMD has 241 employees.

  • What is TherapeuticsMD revenue?

    Latest TherapeuticsMD annual revenue is $16.1 m.

  • What is TherapeuticsMD revenue per employee?

    Latest TherapeuticsMD revenue per employee is $66.8 k.

  • Who are TherapeuticsMD competitors?

    Competitors of TherapeuticsMD include Shire, Ogeda and Mithra.

  • Where is TherapeuticsMD headquarters?

    TherapeuticsMD headquarters is located at 6800 Broken Sound Pkwy NW, Boca Raton.

  • Where are TherapeuticsMD offices?

    TherapeuticsMD has an office in Boca Raton.

  • How many offices does TherapeuticsMD have?

    TherapeuticsMD has 1 office.